Management of Acute Myocardial Infarction in the Presence of Left Bundle Branch Block
NCT ID: NCT01494870
Last Updated: 2012-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
300 participants
INTERVENTIONAL
2012-01-31
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
β Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure
NCT02786654
Study to Evaluate the Care Process and the Quality of STEMI Care
NCT02961777
Acute and Long-term Outcomes of Patients With Acute Myocardial Infarction Treated With PCI
NCT04506047
Left Main Intervention in Myocardial Infarction and Acute Coronary Syndromes
NCT05701319
Postconditioning in Primary PCI and Direct Stenting
NCT00351247
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
According to the ESC'2008 and ACC/AHA'2009 focused update guidelines patients admitted to the hospital within 12 hours after the onset of chest pain with new (or presumably new) left bundle-branch block (LBBB) should be treated like patients having STEMI (class I, level A). However, it is well-known that in patients with concomitant LBBB, the ECG manifestations of acute myocardial injury may be masked.
ACS may occur in a patient with "true old" LBBB (when doctor has/has not an ability to compare the new ECG with the previous one) or (presumably) new LBBB.
There is a high risk of non receiving appropriate therapy or of receiving inappropriate therapy (thrombolysis instead of LMWH/UFH/fondaparinux).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PCI
urgent PCI on admission
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Ischemic discomfort (ie, ischemic chest pain or equivalent) at rest ≥20 minutes within previous 24 hours.
* Any (new, presumably new, or old) LBBB on the prehospital (ambulance) or admission ECG.
* Urgent coronary angiography (followed, when indicated, by PCI), ideally within 90 minutes after admission
Exclusion Criteria
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Samara Regional Cardiology Dispensary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ass.Prof. Dmitry Duplyakov M.D., Ph.D.
Medical Director, Cardiology Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Samara Regional Cardiology Dispansery
Samara, , Russia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SOKKD-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.